Latest Hotspot

The Phase 3 LUNA 3 trial of Rilzabrutinib successfully achieved its main goal in treating immune thrombocytopenia

25 April 2024
3 min read

The recent LUNA 3 phase 3 trial findings showed that administering 400 mg of rilzabrutinib orally twice daily effectively met the primary goal of sustaining platelet response in adults suffering from persistent or chronic immune thrombocytopenia. Rilzabrutinib's safety characteristics were in line with those observed in earlier research.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The LUNA 3 trial successfully reached its primary objective, showing a significant percentage of individuals treated with rilzabrutinib had a sustained platelet response when compared to those given a placebo. This important outcome was observed in a group of patients with primary ITP who did not respond to previous treatments.

Participants in the study previously had an average of four different ITP therapies and entered the study with a median platelet count of 15,000/μL. Furthermore, significant improvements in critical secondary objectives further highlight the therapeutic promise of rilzabrutinib for those affected by long-standing and chronic ITP.

In November 2020, the US Food and Drug Administration assigned Fast Track Designation to rilzabrutinib for the management of ITP. Furthermore, the drug had already received Orphan Drug Designation.

Houman Ashrafian, the Executive Vice President, Head of Research and Development at Sanofi, remarked, “This study's findings bolster the vision of rilzabrutinib as a pioneering oral, reversible BTK inhibitor capable of offering meaningful clinical improvement to people affected by severe immune-related conditions such as ITP. These critical findings affirm our dedication and proficiency in addressing rare hematological conditions and our capacity to develop a new generation of tailored and selective small-molecule inhibitors, which show enhanced effectiveness and safety profiles when compared to existing treatments.”

ITP represents a severe, acquired autoimmune blood condition defined by the immune-driven destruction of platelets and reduced platelet production, leading to thrombocytopenia and elevated risks of severe bleeding. 

Furthermore, ITP patients frequently suffer from notable declines in life quality, experiencing issues like fatigue and cognitive impairments. Through its dual action mechanism that both lowers the production of harmful autoantibodies and reduces macrophage-driven platelet destruction, rilzabrutinib has the potential to tackle the core causes of various ITP-related complications.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of April 24, 2024, there are 185 investigational drugs for the BTK target, including 189 indications, 225 R&D institutions involved, with related clinical trials reaching 1322, and as many as 18084 patents.

Rilzabrutinib has reached Phase 3 in clinical development globally and in China. The drug shows potential in treating various immune-related disorders and has been designated as an orphan drug. Further research and clinical trials will be necessary to determine its safety and efficacy in treating the indicated conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
Latest Hotspot
3 min read
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
25 April 2024
ImmunityBio Receives FDA Nod for ANKTIVA®, a Novel IL-15 Receptor Stimulator, for Treating BCG-Resistant Non-Muscle Invasive Bladder Cancer.
Read →
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
Latest Hotspot
3 min read
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
25 April 2024
Neurogene Set to Reveal NGN-401 Gene Therapy Safety Results from Early Stage Trial for Rett Syndrome during ASGCT Conference.
Read →
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
Latest Hotspot
3 min read
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
25 April 2024
Adicet Bio presents preclinical findings indicating IND preparedness for ADI-270 during a talk at the 27th Annual ASGCT Meeting.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 25
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 25
25 April 2024
April 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.